<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-id journal-id-type="iso-abbrev">Diabetologia</journal-id><journal-title-group><journal-title>Diabetologia</journal-title></journal-title-group><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24026211</article-id><article-id pub-id-type="pmc">3825495</article-id><article-id pub-id-type="publisher-id">3039</article-id><article-id pub-id-type="doi">10.1007/s00125-013-3039-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lavalle-Gonz&#x000e1;lez</surname><given-names>F. J.</given-names></name><address><email>drfernandolavalle@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Januszewicz</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Davidson</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Tong</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Canovatchel</surname><given-names>W.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Meininger</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Endocrinology and Internal Medicine Department, Universidad Auton&#x000f3;ma de Nuevo Le&#x000f3;n, Avenida Madero y Gonzalitos, S/N Col. Mitras Centro, 64460 Monterrey, Nuevo Le&#x000f3;n Mexico </aff><aff id="Aff2"><label/>Department of Hypertension, Institute of Cardiology, Warsaw, Poland </aff><aff id="Aff3"><label/>Department of Medicine, University of Texas Southwestern Medical School, Dallas, TX USA </aff><aff id="Aff4"><label/>Janssen Research &#x00026; Development, LLC, Raritan, NJ USA </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2013</year></pub-date><volume>56</volume><issue>12</issue><fpage>2582</fpage><lpage>2592</lpage><history><date date-type="received"><day>15</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Aims/hypothesis</title><p>The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being treated with background metformin.</p></sec><sec><title>Methods</title><p>This randomised, double-blind, four-arm, parallel-group, Phase 3 study was conducted at 169 centres in 22 countries between April 2010 and August 2012. Participants (<italic>N</italic>&#x02009;=&#x02009;1,284) with type 2 diabetes aged &#x02265;18 and &#x02264;80 years who had inadequate glycaemic control (HbA<sub>1c</sub> &#x02265;7.0% [53&#x000a0;mmol/mol] and &#x02264;10.5% [91&#x000a0;mmol/mol]) on metformin therapy received canagliflozin 100&#x000a0;mg or 300&#x000a0;mg, sitagliptin 100&#x000a0;mg, or placebo (<italic>n</italic>&#x02009;=&#x02009;368, 367, 366, 183, respectively) for a 26&#x000a0;week, placebo- and active-controlled period followed by a 26&#x000a0;week, active-controlled period (placebo group switched to sitagliptin [placebo/sitagliptin]) and were included in the modified intent-to-treat analysis set. Randomisation was performed using a computer-generated schedule; participants, study centres and the sponsor were blinded to group assignment. The primary endpoint was change from baseline in HbA<sub>1c</sub> at week&#x000a0;26; secondary endpoints included changes in HbA<sub>1c</sub> (week&#x000a0;52) and fasting plasma glucose (FPG), body weight, and systolic blood pressure (BP; weeks&#x000a0;26 and 52). Adverse events (AEs) were recorded throughout the study.</p></sec><sec><title>Results</title><p>At week&#x000a0;26, canagliflozin 100&#x000a0;mg and 300&#x000a0;mg reduced HbA<sub>1c</sub> vs placebo (&#x02212;0.79%, &#x02013;0.94%, &#x02013;0.17%, respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). At week&#x000a0;52, canagliflozin 100&#x000a0;mg and 300&#x000a0;mg demonstrated non-inferiority, and canagliflozin 300&#x000a0;mg demonstrated statistical superiority, to sitagliptin in lowering HbA<sub>1c</sub> (&#x02212;0.73%, &#x02013;0.88%,&#x02013;0.73%, respectively); differences (95% CI) vs sitagliptin were 0% (&#x02212;0.12, 0.12) and &#x02212;0.15% (&#x02212;0.27, &#x02013;0.03), respectively. Canagliflozin 100&#x000a0;mg and 300&#x000a0;mg reduced body weight vs placebo (week&#x000a0;26: &#x02013;3.7%, &#x02013;4.2%, &#x02013;1.2%, respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and sitagliptin (week&#x000a0;52: &#x02013;3.8%, &#x02013;4.2%, &#x02013;1.3%, respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Both canagliflozin doses reduced FPG and systolic BP vs placebo (week&#x000a0;26) and sitagliptin (week&#x000a0;52) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Overall AE and AE-related discontinuation rates were generally similar across groups, but higher with canagliflozin 100&#x000a0;mg. Genital mycotic infection and osmotic diuresis-related AE rates were higher with canagliflozin; few led to discontinuations. Hypoglycaemia incidence was higher with canagliflozin.</p></sec><sec><title>Conclusions/interpretation</title><p>Canagliflozin improved glycaemia and reduced body weight vs placebo (week&#x000a0;26) and sitagliptin (week&#x000a0;52) and was generally well tolerated in patients with type 2 diabetes on metformin.</p></sec><sec><title>Clinical trial registry</title><p>ClinicalTrials.gov NCT01106677</p></sec><sec><title>Funding</title><p>This study was supported by Janssen Research &#x00026; Development, LLC.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00125-013-3039-1) contains peer-reviewed but unedited supplementary material, which is available to authorised users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Canagliflozin</kwd><kwd>Metformin</kwd><kwd>Sitagliptin</kwd><kwd>Sodium glucose co-transporter 2 (SGLT2) inhibitor</kwd><kwd>Type 2 diabetes mellitus</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Metformin is the recommended first-line pharmacological therapy for type 2 diabetes but the progressive nature of the disease often necessitates more intensive treatment regimens or combination therapy for patients to achieve and/or maintain glycaemic control [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Currently available antihyperglycaemic agents (AHAs) have distinct risk/benefit profiles, which must be considered when choosing an add-on therapy to metformin that meets the needs of each patient [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of AHAs that are becoming more commonly used as second agents [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor developed for the treatment of patients with type 2 diabetes [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Canagliflozin reduces blood glucose by lowering the renal threshold for glucose and increasing urinary glucose excretion (UGE), resulting in a mild osmotic diuresis and a net caloric loss. In a 12&#x000a0;week study, canagliflozin significantly improved glycaemic control and reduced body weight vs placebo in patients with type 2 diabetes on background metformin, with a low incidence of hypoglycaemia [<xref ref-type="bibr" rid="CR5">5</xref>]. Other SGLT2 inhibitors, dapagliflozin and empagliflozin, have also demonstrated efficacy in lowering HbA<sub>1c</sub> and body weight with a low risk of hypoglycaemia in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. This 52&#x000a0;week Phase 3 study in patients with type 2 diabetes inadequately controlled with metformin monotherapy evaluated the efficacy and safety of canagliflozin compared with placebo at week&#x000a0;26 and sitagliptin at week&#x000a0;52.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Participants and study design</title><p>This randomised, double-blind, placebo- and active-controlled, Phase 3 study (ClinicalTrials.gov NCT01106677) was conducted at 169 centres in 22 countries. The study consisted of a 2&#x000a0;week single-blind, placebo run-in period, a 26&#x000a0;week placebo- and active-controlled, double-blind treatment period (period I) followed by a 26&#x000a0;week active-controlled, double-blind treatment period (period II) and a 4&#x000a0;week follow-up period.</p><p>Eligible participants were men and women with type 2 diabetes, aged &#x02265;18 and &#x02264;80 years, who had inadequate glycaemic control (HbA<sub>1c</sub> &#x02265;7.0% [53&#x000a0;mmol/mol] and &#x02264;10.5% [91&#x000a0;mmol/mol]) and who were on stable metformin therapy (&#x02265;2,000&#x000a0;mg/day [or &#x02265;1,500&#x000a0;mg/day if unable to tolerate higher dose]) for &#x02265;8&#x000a0;weeks and had fasting plasma glucose (FPG) &#x0003c;15&#x000a0;mmol/l at week&#x02009;&#x02212;2 and fasting fingerstick glucose &#x02265;6.1&#x000a0;mmol/l and &#x0003c;15&#x000a0;mmol/l on day&#x000a0;1. Participants on metformin immediate-release (IR) monotherapy at protocol-specified doses at screening directly entered the placebo run-in period. Those on metformin extended release (XR), metformin IR or XR at below protocol-specified doses or metformin plus sulfonylurea underwent a metformin IR dose titration/dose stable and, if applicable, a sulfonylurea washout period of up to 10&#x000a0;weeks, followed by the placebo run-in period.</p><p>The following exclusion criteria were applied: repeated FPG and/or fasting self-monitored blood glucose (SMBG) &#x02265;15.0&#x000a0;mmol/l during the pretreatment phase; history of type 1 diabetes, cardiovascular disease (including myocardial infarction, unstable angina, revascularisation procedure or cerebrovascular accident) in the 3&#x000a0;months before screening or uncontrolled hypertension; treatment with a peroxisome proliferator-activated receptor &#x003b3; agonist, insulin, another SGLT2 inhibitor or any other AHA (except metformin as monotherapy or in combination with a sulfonylurea) in the 12&#x000a0;weeks before screening; or estimated glomerular filtration rate (eGFR) &#x0003c;55&#x000a0;ml&#x000a0;min<sup>&#x02212;1</sup> (1.73&#x000a0;m<sup>2</sup>)<sup>&#x02212;1</sup> (or &#x0003c;60&#x000a0;ml&#x000a0;min<sup>&#x02212;1</sup> [1.73&#x000a0;m<sup>2</sup>]<sup>&#x02212;1</sup> if based upon restriction in local label) or serum creatinine &#x02265;124 &#x003bc;mol/l (men) or &#x02265;115&#x000a0;&#x003bc;mol/l (women).</p><p>The study was conducted in accordance with ethical principles that comply with the Declaration of Helsinki and are consistent with Good Clinical Practices and applicable regulatory requirements. The study protocol and amendments were approved by institutional review boards at participating institutions. All participants provided written informed consent before taking part in the study.</p></sec><sec id="Sec4"><title>Randomisation and treatments</title><p>During the placebo run-in period, participants received single-blind placebo capsules matching study drug once daily. Participants were randomised to receive canagliflozin 100&#x000a0;mg or 300&#x000a0;mg, sitagliptin 100&#x000a0;mg or placebo (2:2:2:1) once daily for 26&#x000a0;weeks. The canagliflozin 100&#x000a0;mg and 300&#x000a0;mg once-daily doses were selected based on findings from a dose-ranging, Phase 2 study in patients with type 2 diabetes on background metformin [<xref ref-type="bibr" rid="CR5">5</xref>]; a 300&#x000a0;mg twice-daily regimen provided only incremental benefits vs the once-daily regimen and was therefore not selected for further development. The use of placebo as a control for the 26&#x000a0;week core treatment period was done in accordance with US Food and Drug Administration and European Medicines Agency regulatory guidelines [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. The computer-generated randomisation schedule was prepared by the sponsor before the study. Randomisation was balanced using permuted blocks of seven and stratified by whether a participant was on metformin monotherapy or metformin plus sulfonylurea at screening. After randomisation, HbA<sub>1c</sub> and FPG values were masked to the study centres unless they met glycaemic rescue criteria. After completion of period I, the database was locked and the study was unblinded by the sponsor for regulatory filing; the participants and the study centre and local sponsor personnel remained blinded throughout period II.</p><p>Participants who completed period I then entered period II, during which those randomised to canagliflozin (100 or 300&#x000a0;mg) or sitagliptin 100&#x000a0;mg continued on those treatments while those randomised to placebo switched to sitagliptin 100&#x000a0;mg in a blinded fashion. During the double-blind treatment period, glycaemic rescue therapy with glimepiride (added to study drug and background metformin) was initiated if FPG &#x0003e;15.0&#x000a0;mmol/l after day&#x000a0;1 to week&#x000a0;6, &#x0003e;13.3&#x000a0;mmol/l after week&#x000a0;6 to week&#x000a0;12, and &#x0003e;11.1&#x000a0;mmol/l after week&#x000a0;12 to week&#x000a0;26. Glimepiride therapy was also started if HbA<sub>1c</sub> &#x0003e;8.0% (64&#x000a0;mmol/mol) after week&#x000a0;26.</p></sec><sec id="Sec5"><title>Endpoints and assessments</title><p>The pre-specified primary efficacy endpoint was change in HbA<sub>1c</sub> from baseline to week&#x000a0;26; change in HbA<sub>1c</sub> from baseline to week&#x000a0;52 was a key, pre-specified secondary endpoint. Other pre-specified secondary endpoints at week&#x000a0;26 were proportion of participants reaching HbA<sub>1c</sub> &#x0003c;7.0% (53&#x000a0;mmol/mol), change in FPG, 2&#x000a0;h postprandial glucose (PPG) and systolic BP and per cent change in body weight, triacylglycerol (i.e. triglycerides) and HDL-cholesterol. All participants underwent a mixed-meal tolerance test (MMTT) on day&#x000a0;1 and at week&#x000a0;26 for assessment of 2&#x000a0;h PPG. Change in Apo B was assessed in a subset of participants at week&#x000a0;26 based on availability of paired baseline and week&#x000a0;26 archive samples. Other pre-specified secondary endpoints at week&#x000a0;52 were change in FPG and systolic BP and per cent change in body weight, triacylglycerol and HDL-cholesterol.</p><p>Safety and tolerability were evaluated based on adverse event (AE) reports, safety laboratory tests, vital sign measurements, physical examinations, SMBG and 12-lead electrocardiograms. AEs pre-specified for additional data collection included urinary tract infections (UTIs) and genital mycotic infections. Documented episodes of hypoglycaemia included biochemically confirmed episodes (concurrent fingerstick or plasma glucose &#x02264;3.9&#x000a0;mmol/l) and/or severe episodes (i.e. requiring the assistance of another individual or resulting in seizure or loss of consciousness).</p></sec><sec id="Sec6"><title>Statistical analyses</title><p>The primary hypothesis was that canagliflozin 300&#x000a0;mg is statistically superior to placebo in reducing HbA<sub>1c</sub> from baseline to week&#x000a0;26. Key secondary hypotheses were statistical superiority of canagliflozin 100&#x000a0;mg to placebo in HbA<sub>1c</sub>- lowering effect at week&#x000a0;26 and non-inferiority of canagliflozin 300&#x000a0;mg or both canagliflozin doses to sitagliptin 100&#x000a0;mg in reducing HbA<sub>1c</sub> from baseline to week&#x000a0;52. Primary efficacy analysis was performed in the modified intent-to-treat (mITT) population (randomised participants who received &#x02265;1 dose of study drug) using a last observation carried forward (LOCF) approach. Assuming a group difference of 0.5% (5.5&#x000a0;mmol/mol) between canagliflozin and placebo and a common SD of 1.0% (10.9&#x000a0;mmol/mol) for change in HbA<sub>1c</sub>, and using a two-sample, two-sided <italic>t</italic> test with a type I error rate of 0.05, an estimated 86 participants per group were required to achieve 90% power to demonstrate statistical superiority of canagliflozin to placebo. To support superiority and non-inferiority objectives for the primary endpoint in the mITT population and for supportive analysis in the per-protocol population (mITT participants who completed the study, did not receive rescue therapy and had no major protocol violations), an estimated 360 randomised participants were needed for each active treatment group and 180 for the placebo group, assuming a 35% discontinuation rate at week&#x000a0;52 and with a 2:2:2:1 randomisation ratio for canagliflozin 100&#x000a0;mg, canagliflozin 300&#x000a0;mg, sitagliptin 100&#x000a0;mg and placebo.</p><p>Primary efficacy analyses were performed in the mITT population according to randomised treatment assignment using LOCF to impute missing data; for participants who received rescue therapy, the last post-baseline value before rescue was used. Safety analyses were performed in the same population according to the predominant treatment received; in this study, the mITT and safety populations were identical. Only data from participants randomised to sitagliptin 100&#x000a0;mg on day&#x000a0;1 (i.e. not including participants who switched from placebo to sitagliptin at week&#x000a0;26) were included in efficacy comparisons at week&#x000a0;52. Safety analyses over 52&#x000a0;weeks included participants who received canagliflozin 100&#x000a0;mg or 300&#x000a0;mg or sitagliptin and those who switched from placebo to sitagliptin after 26&#x000a0;weeks (placebo/sitagliptin group).</p><p>An analysis of covariance (ANCOVA) model with treatment and stratification factor as fixed effects and corresponding baseline value as a covariate was used to assess primary and continuous secondary endpoints. Least squares (LS) mean differences between groups and two-sided 95% CIs were estimated. The categorical secondary endpoint was analysed with a logistic model with treatment and stratification factor as fixed effects and baseline HbA<sub>1c</sub> as a covariate. Assessment of non-inferiority of canagliflozin to sitagliptin was based on a pre-specified margin of 0.3% for the upper limit of the two-sided 95% CI for the comparison. If non-inferiority was demonstrated, then superiority was assessed based on an upper bound of the 95% CI around the between-group differences of &#x0003c;0.0%.</p><p>Comparisons were performed for canagliflozin vs placebo at week&#x000a0;26 and vs sitagliptin at week&#x000a0;52 based on pre-specified hierarchical testing sequences implemented to strongly control overall type I error due to multiplicity. At week&#x000a0;26, statistical tests were interpreted at a two-sided significance level of 5% for all endpoints except change in systolic BP, HDL-cholesterol and triacylglycerol. These were grouped together into two separate families (one each for canagliflozin 100&#x000a0;mg and 300&#x000a0;mg) and each family was tested using the Hochberg procedure at the 2.5% significance level. Comparisons of canagliflozin with sitagliptin at week&#x000a0;52 were initiated after statistical superiority of canagliflozin 100&#x000a0;mg and 300&#x000a0;mg to placebo in HbA<sub>1c</sub> lowering at week&#x000a0;26 was established; statistical tests at week&#x000a0;52 were interpreted at a two-sided significance level of 5% for all endpoints. The <italic>p</italic> values are reported for pre-specified comparisons only.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Participant disposition and baseline characteristics</title><p>A total of 1,284 participants were randomised into period I and received &#x02265;1 dose of study drug (mITT analysis set); of 1,119 participants who completed period I, 1,103 entered period II and 1,020 completed 52&#x000a0;weeks of treatment (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The rate of study discontinuation before week&#x000a0;52 was 19.0%, 18.5%, 22.1% and 24.6% with canagliflozin 100&#x000a0;mg, canagliflozin 300&#x000a0;mg, sitagliptin and placebo/sitagliptin, respectively. Over 52&#x000a0;weeks, the percentage of participants who received glycaemic rescue therapy was 14.7%, 9.3%, 18.0% and 25.1% with canagliflozin 100&#x000a0;mg, canagliflozin 300&#x000a0;mg, sitagliptin and placebo/sitagliptin, respectively (OR [95% CI] with canagliflozin 100&#x000a0;mg and 300&#x000a0;mg, respectively, of 0.78 [0.53, 1.16] and 0.46 [0.30, 0.72] vs sitagliptin, and 0.51 [0.33, 0.80] and 0.30 [0.19, 0.49] vs placebo/sitagliptin). Demographic and baseline characteristics were generally similar across groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Study flow diagram. <sup>a</sup>Among 2,883 patients enrolled and screened, there were 1,599 screen failures (inclusion/exclusion criteria, <italic>n</italic>&#x02009;=&#x02009;1,428; withdrawal of consent, <italic>n</italic>&#x02009;=&#x02009;115; other, <italic>n</italic>&#x02009;=&#x02009;50; adverse event, <italic>n</italic>&#x02009;=&#x02009;6). <sup>b</sup>Some subjects withdrew from the study after completing period I and did not enter period II. CANA, canagliflozin; PBO, placebo; SITA, sitagliptin</p></caption><graphic xlink:href="125_2013_3039_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographics and disease characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>PBO/SITA (<italic>n</italic>&#x02009;=&#x02009;183)</th><th>SITA 100&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;366)</th><th>CANA 100&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;368)</th><th>CANA 300&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;367)</th><th>Total (<italic>N</italic>&#x02009;=&#x02009;1,284)</th></tr></thead><tbody><tr><td colspan="6">Sex, <italic>n</italic> (%)</td></tr><tr><td>&#x02002;&#x02002;Male</td><td>94 (51.4)</td><td>172 (47.0)</td><td>174 (47.3)</td><td>165 (45.0)</td><td>605 (47.1)</td></tr><tr><td>&#x02002;&#x02002;Female</td><td>89 (48.6)</td><td>194 (53.0)</td><td>194 (52.7)</td><td>202 (55.0)</td><td>679 (52.9)</td></tr><tr><td>Age, years</td><td>55.3&#x02009;&#x000b1;&#x02009;9.8</td><td>55.5&#x02009;&#x000b1;&#x02009;9.6</td><td>55.5&#x02009;&#x000b1;&#x02009;9.4</td><td>55.3&#x02009;&#x000b1;&#x02009;9.2</td><td>55.4&#x02009;&#x000b1;&#x02009;9.4</td></tr><tr><td colspan="6">Race, <italic>n</italic> (%)</td></tr><tr><td>&#x02002;&#x02002;White</td><td>129 (70.5)</td><td>264 (72.1)</td><td>252 (68.5)</td><td>256 (69.8)</td><td>901 (70.2)</td></tr><tr><td>&#x02002;&#x02002;Black or African-American</td><td>3 (1.6)</td><td>13 (3.6)</td><td>16 (4.3)</td><td>13 (3.5)</td><td>45 (3.5)</td></tr><tr><td>&#x02002;&#x02002;Asian</td><td>30 (16.4)</td><td>41 (11.2)</td><td>51 (13.9)</td><td>60 (16.3)</td><td>182 (14.2)</td></tr><tr><td>&#x02002;&#x02002;Other<sup>a</sup>
</td><td>21 (11.5)</td><td>48 (13.1)</td><td>49 (13.3)</td><td>38 (10.4)</td><td>156 (12.1)</td></tr><tr><td>HbA<sub>1c</sub>, % (mmol/mol)</td><td>8.0&#x02009;&#x000b1;&#x02009;0.9 (64&#x02009;&#x000b1;&#x02009;9.8)</td><td>7.9&#x02009;&#x000b1;&#x02009;0.9 (63&#x02009;&#x000b1;&#x02009;9.8)</td><td>7.9&#x02009;&#x000b1;&#x02009;0.9 (63&#x02009;&#x000b1;&#x02009;9.8)</td><td>7.9&#x02009;&#x000b1;&#x02009;0.9 (63&#x02009;&#x000b1;&#x02009;9.8)</td><td>7.9&#x02009;&#x000b1;&#x02009;0.9 (63&#x02009;&#x000b1;&#x02009;9.8)</td></tr><tr><td>FPG, mmol/l</td><td>9.1&#x02009;&#x000b1;&#x02009;2.1</td><td>9.4&#x02009;&#x000b1;&#x02009;2.3</td><td>9.3&#x02009;&#x000b1;&#x02009;2.3</td><td>9.6&#x02009;&#x000b1;&#x02009;2.5</td><td>9.4&#x02009;&#x000b1;&#x02009;2.3</td></tr><tr><td>Body weight, kg</td><td>86.6&#x02009;&#x000b1;&#x02009;22.4</td><td>87.7&#x02009;&#x000b1;&#x02009;21.6</td><td>88.8&#x02009;&#x000b1;&#x02009;22.2</td><td>85.4&#x02009;&#x000b1;&#x02009;20.9</td><td>87.2&#x02009;&#x000b1;&#x02009;21.7</td></tr><tr><td>BMI, kg/m<sup>2</sup>
</td><td>31.1&#x02009;&#x000b1;&#x02009;6.1</td><td>32.0&#x02009;&#x000b1;&#x02009;6.1</td><td>32.4&#x02009;&#x000b1;&#x02009;6.4</td><td>31.4&#x02009;&#x000b1;&#x02009;6.3</td><td>31.8&#x02009;&#x000b1;&#x02009;6.2</td></tr><tr><td>Duration of diabetes, years</td><td>6.8&#x02009;&#x000b1;&#x02009;5.3</td><td>6.8&#x02009;&#x000b1;&#x02009;5.2</td><td>6.7&#x02009;&#x000b1;&#x02009;5.4</td><td>7.1&#x02009;&#x000b1;&#x02009;5.4</td><td>6.9&#x02009;&#x000b1;&#x02009;5.3</td></tr></tbody></table><table-wrap-foot><p>Data are mean &#x000b1; SD unless otherwise indicated</p><p>
<sup>a</sup>Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple and other</p><p>CANA, canagliflozin; PBO, placebo; SITA, sitagliptin</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Effect on glycaemic variables</title><sec id="d30e948"><title>Week&#x000a0;26 (period I only)</title><p>At week&#x000a0;26, canagliflozin 100&#x000a0;mg and 300&#x000a0;mg significantly reduced HbA<sub>1c</sub> from baseline compared with placebo (difference in LS mean changes of &#x02212;0.62% and &#x02212;0.77% [&#x02212;6.8 and &#x02212;8.4&#x000a0;mmol/mol], respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 for both); the change in HbA<sub>1c</sub> with sitagliptin was &#x02212;0.66% (&#x02212;7.2&#x000a0;mmol/mol) relative to placebo (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>; electronic supplementary material [ESM] Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>). Statistical comparison of canagliflozin with sitagliptin at week&#x000a0;26 was not performed (not pre-specified). A greater proportion of participants treated with canagliflozin 100&#x000a0;mg and 300&#x000a0;mg achieved HbA<sub>1c</sub> &#x0003c;7.0% (53&#x000a0;mmol/mol) than with placebo (45.5%, 57.8% and 29.8%, respectively; <italic>p</italic>&#x02009;=&#x02009;0.000 for both); 54.5% of sitagliptin-treated participants achieved HbA<sub>1c</sub> &#x0003c;7.0% (53&#x000a0;mmol/mol). Both canagliflozin doses significantly reduced FPG and 2&#x000a0;h PPG at week&#x000a0;26 vs placebo (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 for all; ESM Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>); FPG and 2&#x000a0;h PPG were also reduced from baseline with sitagliptin.<fig id="Fig2"><label>Fig. 2</label><caption><p>Changes in glycaemic variables (LOCF). (<bold>a</bold>) Change in HbA<sub>1c</sub> at week&#x000a0;26, (<bold>b</bold>) change in HbA<sub>1c</sub> at week&#x000a0;52, (<bold>c</bold>) mean HbA<sub>1c</sub> over time and (<bold>d</bold>) change in FPG at week&#x000a0;52. CANA, canagliflozin; PBO, placebo; SITA, sitagliptin. Light-grey triangles, PBO; white diamonds, SITA 100&#x000a0;mg; dark-grey squares, CANA 100&#x000a0;mg; black circles, CANA 300&#x000a0;mg. Error bars show SE. To convert values for HbA<sub>1c</sub> in % into mmol/mol, subtract 2.15 and multiply by 10.929 or use the conversion calculator at <ext-link ext-link-type="uri" xlink:href="http://www.hba1c.nu/eng/">www.HbA1c.nu/eng/</ext-link>
</p></caption><graphic xlink:href="125_2013_3039_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="d30e1023"><title>Week&#x000a0;52 (periods I and II)</title><p>At 52&#x000a0;weeks, canagliflozin 100&#x000a0;mg and 300&#x000a0;mg demonstrated non-inferiority to sitagliptin 100&#x000a0;mg in HbA<sub>1c</sub>-lowering effect (upper limit of the 95% CI less than pre-specified margin of 0.3%; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b, c</xref>; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Canagliflozin 300&#x000a0;mg demonstrated statistical superiority to sitagliptin in HbA<sub>1c</sub>-lowering effect (upper limit of the 95% CI less than 0.0%). The difference in LS mean changes (95% CI) for canagliflozin 100&#x000a0;mg and 300&#x000a0;mg vs sitagliptin was 0% (&#x02212;0.12, 0.12) or 0&#x000a0;mmol/mol (&#x02212;1.3, 1.3) and &#x02212;0.15% (&#x02212;0.27, &#x02013;0.03) or &#x02212;1.6&#x000a0;mmol/mol (&#x02212;3.0, &#x02013;0.3), respectively. The separation in treatment effect between canagliflozin 300&#x000a0;mg and sitagliptin was observed starting at week&#x000a0;6 and continued through week&#x000a0;52. A higher proportion of participants treated with canagliflozin 300&#x000a0;mg achieved HbA<sub>1c</sub> &#x0003c;7.0% (53&#x000a0;mmol/mol) compared with those treated with canagliflozin 100&#x000a0;mg or sitagliptin (54.7%, 41.4% and 50.6%, respectively; OR [95% CI] of 1.28 [0.92, 1.76] and 0.66 [0.48, 0.91] with canagliflozin 300&#x000a0;mg and 100&#x000a0;mg vs sitagliptin). The proportion of participants reaching HbA<sub>1c</sub> &#x0003c;6.5% (48&#x000a0;mmol/mol) was 26.9%, 21.9% and 24.9% for those treated with canagliflozin 300&#x000a0;mg, canagliflozin 100&#x000a0;mg and sitagliptin, respectively (OR 1.14 [0.80, 1.62] and 0.84 [0.59, 1.22], respectively). Over 52&#x000a0;weeks, canagliflozin 100&#x000a0;mg and 300&#x000a0;mg provided greater reductions in FPG than sitagliptin (difference in LS mean changes of &#x02212;0.5 and &#x02212;1.0&#x000a0;mmol/l, respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 for both; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), with maximal reductions at 26&#x000a0;weeks across groups.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of efficacy findings at week&#x000a0;52 (LOCF)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>SITA 100&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;366)</th><th>CANA 100&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;368)</th><th>CANA 300&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;367)</th></tr></thead><tbody><tr><td>HbA<sub>1c</sub>, <italic>n</italic>
</td><td>354</td><td>365</td><td>360</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, % (mmol/mol)</td><td>7.9&#x02009;&#x000b1;&#x02009;0.9 (63&#x02009;&#x000b1;&#x02009;9.8)</td><td>7.9&#x02009;&#x000b1;&#x02009;0.9 (63&#x02009;&#x000b1;&#x02009;9.8)</td><td>8.0&#x02009;&#x000b1;&#x02009;0.9 (64&#x02009;&#x000b1;&#x02009;9.8)</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change, % (mmol/mol)</td><td>&#x02212;0.73&#x02009;&#x000b1;&#x02009;0.05 (&#x02212;8.0&#x02009;&#x000b1;&#x02009;0.5)</td><td>&#x02212;0.73&#x02009;&#x000b1;&#x02009;0.05 (&#x02212;8.0&#x02009;&#x000b1;&#x02009;0.5)</td><td>&#x02212;0.88&#x02009;&#x000b1;&#x02009;0.05 (&#x02212;9.6&#x02009;&#x000b1;&#x02009;0.5)</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI), %</td><td/><td>0.00 (&#x02212;0.12, 0.12)</td><td>&#x02212;0.15 (&#x02212;0.27, &#x02013;0.03)</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI), mmol/mol</td><td/><td>0.0 (&#x02212;1.3, 1.3)</td><td>&#x02212;1.6 (&#x02212;3.0, &#x02013;0.3)</td></tr><tr><td>FPG, <italic>n</italic>
</td><td>354</td><td>365</td><td>360</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, mmol/l</td><td>9.4&#x02009;&#x000b1;&#x02009;2.3</td><td>9.4&#x02009;&#x000b1;&#x02009;2.3</td><td>9.6&#x02009;&#x000b1;&#x02009;2.5</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change</td><td>&#x02212;1.0&#x02009;&#x000b1;&#x02009;0.1</td><td>&#x02212;1.5&#x02009;&#x000b1;&#x02009;0.1</td><td>&#x02212;2.0&#x02009;&#x000b1;&#x02009;0.1</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>&#x02212;0.5 (&#x02212;0.7, &#x02013;0.2)<sup>a</sup>
</td><td>&#x02212;1.0 (&#x02212;1.2, &#x02013;0.7)<sup>a</sup>
</td></tr><tr><td>Body weight, <italic>n</italic>
</td><td>355</td><td>365</td><td>360</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, kg</td><td>87.6&#x02009;&#x000b1;&#x02009;20.9</td><td>88.7&#x02009;&#x000b1;&#x02009;22.3</td><td>85.4&#x02009;&#x000b1;&#x02009;20.7</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change, kg</td><td>&#x02212;1.2&#x02009;&#x000b1;&#x02009;0.2</td><td>&#x02212;3.3&#x02009;&#x000b1;&#x02009;0.2</td><td>&#x02212;3.7&#x02009;&#x000b1;&#x02009;0.2</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE per cent change</td><td>&#x02212;1.3&#x02009;&#x000b1;&#x02009;0.2</td><td>&#x02212;3.8&#x02009;&#x000b1;&#x02009;0.2</td><td>&#x02212;4.2&#x02009;&#x000b1;&#x02009;0.2</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>&#x02212;2.4 (&#x02212;3.0, &#x02013;1.8)<sup>a</sup>
</td><td>&#x02212;2.9 (&#x02212;3.4, &#x02013;2.3)<sup>a</sup>
</td></tr><tr><td>Systolic BP, <italic>n</italic>
</td><td>355</td><td>365</td><td>360</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, mmHg</td><td>128.0&#x02009;&#x000b1;&#x02009;13.5</td><td>128.0&#x02009;&#x000b1;&#x02009;12.7</td><td>128.7&#x02009;&#x000b1;&#x02009;13.0</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change</td><td>&#x02212;0.7&#x02009;&#x000b1;&#x02009;0.6</td><td>&#x02212;3.5&#x02009;&#x000b1;&#x02009;0.6</td><td>&#x02212;4.7&#x02009;&#x000b1;&#x02009;0.6</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>&#x02212;2.9 (&#x02212;4.5, &#x02013;1.3)<sup>a</sup>
</td><td>&#x02212;4.0 (&#x02212;5.6, &#x02013;2.4)<sup>a</sup>
</td></tr><tr><td>Diastolic BP, <italic>n</italic>
</td><td>355</td><td>365</td><td>360</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, mmHg</td><td>77.5&#x02009;&#x000b1;&#x02009;8.0</td><td>77.7&#x02009;&#x000b1;&#x02009;8.4</td><td>77.9&#x02009;&#x000b1;&#x02009;8.3</td></tr><tr><td>&#x02003;LS mean &#x02009;&#x000b1; SE change</td><td>&#x02212;0.3&#x02009;&#x000b1;&#x02009;0.4</td><td>&#x02212;1.8&#x02009;&#x000b1;&#x02009;0.4</td><td>&#x02212;1.8&#x02009;&#x000b1;&#x02009;0.4</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>&#x02212;1.4 (&#x02212;2.4, &#x02013;0.5)<sup>b</sup>
</td><td>&#x02212;1.5 (&#x02212;2.5, &#x02013;0.5)<sup>b</sup>
</td></tr><tr><td>Triacylglycerol, <italic>n</italic>
</td><td>339</td><td>359</td><td>343</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, mmol/l</td><td>2.0&#x02009;&#x000b1;&#x02009;1.1</td><td>2.2&#x02009;&#x000b1;&#x02009;1.6</td><td>2.1&#x02009;&#x000b1;&#x02009;1.5</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change</td><td>&#x02212;0.15&#x02009;&#x000b1;&#x02009;0.05</td><td>&#x02212;0.12&#x02009;&#x000b1;&#x02009;0.05</td><td>&#x02212;0.19&#x02009;&#x000b1;&#x02009;0.05</td></tr><tr><td>&#x02003;Median (IQR) per cent change</td><td>&#x02212;3.3 (&#x02212;22.8, 16.7)</td><td>&#x02212;2.7 (&#x02212;28.4, 22.5)</td><td>&#x02212;8.7 (&#x02212;29.1, 23.3)</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE per cent change</td><td>&#x02212;0.4&#x02009;&#x000b1;&#x02009;2.5</td><td>1.9&#x02009;&#x000b1;&#x02009;2.4</td><td>2.8&#x02009;&#x000b1;&#x02009;2.4</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>2.3 (&#x02212;3.9, 8.5)<sup>c</sup>
</td><td>3.2 (&#x02212;3.1, 9.5)<sup>c</sup>
</td></tr><tr><td>LDL-cholesterol, <italic>n</italic>
</td><td>338</td><td>358</td><td>343</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, mmol/l</td><td>2.8&#x02009;&#x000b1;&#x02009;0.9</td><td>2.8&#x02009;&#x000b1;&#x02009;0.8</td><td>2.8&#x02009;&#x000b1;&#x02009;0.9</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change</td><td>0.08&#x02009;&#x000b1;&#x02009;0.04</td><td>0.11&#x02009;&#x000b1;&#x02009;0.04</td><td>0.11&#x02009;&#x000b1;&#x02009;0.04</td></tr><tr><td>&#x02003;Median (IQR) per cent change</td><td>0.9 (&#x02212;9.6, 16.8)</td><td>6.0 (&#x02212;9.9, 21.8)</td><td>5.3 (&#x02212;8.8, 22.6)</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE per cent change</td><td>6.0&#x02009;&#x000b1;&#x02009;1.8</td><td>7.7&#x02009;&#x000b1;&#x02009;1.7</td><td>8.8&#x02009;&#x000b1;&#x02009;1.8</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>1.7 (&#x02212;2.8, 6.2)<sup>b</sup>
</td><td>2.8 (&#x02212;1.8, 7.4)<sup>b</sup>
</td></tr><tr><td>HDL-cholesterol, <italic>n</italic>
</td><td>338</td><td>359</td><td>343</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, mmol/l</td><td>1.2&#x02009;&#x000b1;&#x02009;0.3</td><td>1.2&#x02009;&#x000b1;&#x02009;0.3</td><td>1.2&#x02009;&#x000b1;&#x02009;0.3</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change</td><td>0.06&#x02009;&#x000b1;&#x02009;0.01</td><td>0.12&#x02009;&#x000b1;&#x02009;0.01</td><td>0.14&#x02009;&#x000b1;&#x02009;0.01</td></tr><tr><td>&#x02003;Median (IQR) per cent change</td><td>4.4 (&#x02212;4.0, 14.8)</td><td>8.0 (0.0, 19.8)</td><td>11.1 (0.0, 22.8)</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE per cent change</td><td>6.0&#x02009;&#x000b1;&#x02009;1.1</td><td>11.2&#x02009;&#x000b1;&#x02009;1.0</td><td>13.2&#x02009;&#x000b1;&#x02009;1.1</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>5.2 (2.5, 7.9)<sup>d</sup>
</td><td>7.2 (4.4, 10.0)<sup>d</sup>
</td></tr><tr><td>LDL-cholesterol/HDL-cholesterol, <italic>n</italic>
</td><td>338</td><td>358</td><td>343</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, mol/mol</td><td>2.6&#x02009;&#x000b1;&#x02009;1.0</td><td>2.5&#x02009;&#x000b1;&#x02009;0.9</td><td>2.4&#x02009;&#x000b1;&#x02009;0.9</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change</td><td>&#x02212;0.04&#x02009;&#x000b1;&#x02009;0.04</td><td>&#x02212;0.13&#x02009;&#x000b1;&#x02009;0.04</td><td>&#x02212;0.15&#x02009;&#x000b1;&#x02009;0.04</td></tr><tr><td>&#x02003;Median (IQR) per cent change</td><td>&#x02212;1.7 (&#x02212;14.1, 14.6)</td><td>&#x02212;5.3 (&#x02212;19.3, 11.7)</td><td>&#x02212;4.3 (&#x02212;18.1, 13.2)</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE per cent change</td><td>1.6&#x02009;&#x000b1;&#x02009;1.8</td><td>&#x02212;0.8&#x02009;&#x000b1;&#x02009;1.8</td><td>&#x02212;1.3&#x02009;&#x000b1;&#x02009;1.8</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>&#x02212;2.4 (&#x02212;7.1, 2.2)<sup>b</sup>
</td><td>&#x02212;2.9 (&#x02212;7.6, 1.8)<sup>b</sup>
</td></tr><tr><td>Non-HDL-cholesterol, <italic>n</italic>
</td><td>337</td><td>357</td><td>340</td></tr><tr><td>&#x02003;Mean &#x000b1; SD baseline, mmol/l</td><td>3.7&#x02009;&#x000b1;&#x02009;1.0</td><td>3.8&#x02009;&#x000b1;&#x02009;1.1</td><td>3.7&#x02009;&#x000b1;&#x02009;1.0</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE change</td><td>0.03&#x02009;&#x000b1;&#x02009;0.05</td><td>0.04&#x02009;&#x000b1;&#x02009;0.05</td><td>0.05&#x02009;&#x000b1;&#x02009;0.05</td></tr><tr><td>&#x02003;Median (IQR) per cent change</td><td>1.9 (&#x02212;9.7, 13.7)</td><td>2.4 (&#x02212;8.8, 14.8)</td><td>2.8 (&#x02212;8.3, 18.8)</td></tr><tr><td>&#x02003;LS mean &#x000b1; SE per cent change</td><td>2.8&#x02009;&#x000b1;&#x02009;1.4</td><td>3.8&#x02009;&#x000b1;&#x02009;1.3</td><td>4.0&#x02009;&#x000b1;&#x02009;1.4</td></tr><tr><td>&#x02003;&#x02003;Difference vs SITA (95% CI)</td><td/><td>0.9 (&#x02212;2.6, 4.4)<sup>b</sup>
</td><td>1.1 (&#x02212;2.4, 4.7)<sup>b</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs SITA</p><p>
<sup>b</sup>Statistical comparison vs SITA not performed (not pre-specified)</p><p>
<sup>c</sup>
<italic>p</italic>&#x02009;=&#x02009;NS vs SITA</p><p>
<sup>d</sup>Statistical comparison vs SITA not performed due to multiplicity control</p><p>CANA, canagliflozin; IQR, interquartile range; SITA, sitagliptin</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec10"><title>Effect on body weight, BP and lipids</title><sec id="d30e1869"><title>Week&#x000a0;26 (period I only)</title><p>At week&#x000a0;26, canagliflozin 100&#x000a0;mg and 300&#x000a0;mg significantly reduced body weight compared with placebo (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; ESM Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>); body weight change was &#x02212;1.2% with both sitagliptin and placebo. Both canagliflozin doses were associated with significant decreases vs placebo in systolic BP (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 for both; ESM Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>). Reductions from baseline in diastolic BP were also observed with both canagliflozin doses. Sitagliptin was associated with decreases from baseline in systolic and diastolic BP.</p><p>Both canagliflozin doses significantly increased HDL-cholesterol compared with placebo at week&#x000a0;26 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001); no statistically significant changes in triacylglycerol were seen with canagliflozin relative to placebo (ESM Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>). Statistical testing was not performed (not pre-specified) for other lipid variables, but 95% CIs for between-group comparisons in these variables are reported in ESM Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>. Increases from baseline in LDL-cholesterol were seen with canagliflozin and placebo. In a subset of participants with adequate archived samples for analysis of Apo B (<italic>n</italic>&#x02009;=&#x02009;586), increases from baseline of 4.3%, 5.4% and 2.4% were seen with canagliflozin 100&#x000a0;mg and 300&#x000a0;mg and placebo, respectively. Increases from baseline in triacylglycerol, HDL-cholesterol and LDL-cholesterol were observed with sitagliptin.</p></sec><sec id="d30e1900"><title>Week&#x000a0;52 (periods I and II)</title><p>At week&#x000a0;52, canagliflozin 100&#x000a0;mg and 300&#x000a0;mg significantly reduced body weight compared with sitagliptin (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), with differences in LS mean per cent changes vs sitagliptin of &#x02212;2.4% (&#x02212;2.1&#x000a0;kg) and &#x02212;2.9% (&#x02212;2.5&#x000a0;kg), respectively (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 for both). Weight loss occurred most rapidly with canagliflozin up to week&#x000a0;6, with a continuing, slower decrease followed by an apparent plateau after week&#x000a0;34. A small, gradual decrease from baseline was observed with sitagliptin, which also plateaued after week&#x000a0;34.<fig id="Fig3"><label>Fig. 3</label><caption><p>Per cent change in body weight (LOCF). CANA, canagliflozin; SITA, sitagliptin. White diamonds, SITA 100&#x000a0;mg; dark-grey squares, CANA 100&#x000a0;mg; black circles, CANA 300&#x000a0;mg. Error bars show SE</p></caption><graphic xlink:href="125_2013_3039_Fig3_HTML" id="MO3"/></fig></p><p>Canagliflozin 100&#x000a0;mg and 300&#x000a0;mg significantly decreased systolic BP relative to sitagliptin at 52&#x000a0;weeks (difference in LS mean changes of &#x02212;2.9 and &#x02212;4.0&#x000a0;mmHg, respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 for both; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The change in diastolic BP from baseline was &#x02212;1.8&#x000a0;mmHg with both canagliflozin doses and &#x02212;0.3&#x000a0;mmHg with sitagliptin. No notable differences were observed across groups in changes in pulse rate (&#x02212;1.3, &#x02013;1.9 and &#x02212;1.4 beats/min with canagliflozin 100&#x000a0;mg, canagliflozin 300&#x000a0;mg and sitagliptin, respectively).</p><p>At week&#x000a0;52, increases in triacylglycerol from baseline were seen with both canagliflozin doses, whereas a decrease was observed with sitagliptin; the difference between canagliflozin and sitagliptin did not reach statistical significance (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Median per cent decreases in triacylglycerol were observed across all groups. Both canagliflozin doses increased HDL-cholesterol, but statistical comparison of canagliflozin vs sitagliptin was not performed due to the hierarchical statistical testing sequence. Statistical testing was not performed (not pre-specified) for other lipid variables, but 95% CIs for between-group comparisons in these variables are reported in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The 100&#x000a0;mg and 300&#x000a0;mg dosages of canagliflozin were associated with increases from baseline in LDL-cholesterol and increases in non-HDL-cholesterol that were smaller than those in LDL-cholesterol. Decreases from baseline in the LDL-cholesterol/HDL-cholesterol ratio were observed with both canagliflozin doses, whereas an increase was seen with sitagliptin.</p></sec></sec><sec id="Sec11"><title>Safety and tolerability</title><p>Overall incidences of AEs and AE-related discontinuations were generally comparable across groups over 52&#x000a0;weeks, with slightly higher incidences in the group receiving canagliflozin 100&#x000a0;mg (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The higher incidence of AE-related discontinuations with canagliflozin 100&#x000a0;mg was not due to an increase in any specific AE. The incidence of AEs related to the study drug was higher with canagliflozin and sitagliptin than with placebo/sitagliptin; the incidence of serious AEs was low and similar across groups. The overall incidence of AEs that occurred in period II was similar across groups; the incidence of AEs related to study drug in period II was higher with canagliflozin and sitagliptin than with placebo/sitagliptin (ESM Table&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>). During period II, the incidence of AEs leading to discontinuation was higher in the sitagliptin group than in the other groups, as was the incidence of serious AEs.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of overall safety and selected AEs over 52 weeks</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">AE</th><th colspan="4">No. (%) of participants</th></tr><tr><th>PBO/SITA (<italic>n</italic>&#x02009;=&#x02009;183)</th><th>SITA 100 mg (<italic>n</italic>&#x02009;=&#x02009;366)</th><th>CANA 100 mg (<italic>n</italic>&#x02009;=&#x02009;368)</th><th>CANA 300 mg (<italic>n</italic>&#x02009;=&#x02009;367)</th></tr></thead><tbody><tr><td>Any AE</td><td>122 (66.7)</td><td>236 (64.5)</td><td>266 (72.3)</td><td>230 (62.7)</td></tr><tr><td>AEs leading to discontinuation</td><td>8 (4.4)</td><td>16 (4.4)</td><td>19 (5.2)</td><td>12 (3.3)</td></tr><tr><td>AEs related to study drug<sup>a</sup>
</td><td>23 (12.6)</td><td>72 (19.7)</td><td>97 (26.4)</td><td>73 (19.9)</td></tr><tr><td>Serious AEs</td><td>7 (3.8)</td><td>18 (4.9)</td><td>15 (4.1)</td><td>12 (3.3)</td></tr><tr><td>Deaths</td><td>1 (0.5)</td><td>1 (0.3)</td><td>0</td><td>1 (0.3)</td></tr><tr><td>Selected AEs</td><td/><td/><td/><td/></tr><tr><td>&#x02003;UTI</td><td>12 (6.6)</td><td>23 (6.3)</td><td>29 (7.9)</td><td>18 (4.9)</td></tr><tr><td colspan="5">&#x02003;Genital mycotic infection</td></tr><tr><td>&#x02003;&#x02003;Men<sup>b,c</sup>
</td><td>1 (1.1)</td><td>2 (1.2)</td><td>9 (5.2)</td><td>4 (2.4)</td></tr><tr><td>&#x02003;&#x02003;Women<sup>d,e</sup>
</td><td>1 (1.1)</td><td>5 (2.6)</td><td>22 (11.3)</td><td>20 (9.9)</td></tr><tr><td colspan="5">&#x02003;Osmotic diuresis-related AEs</td></tr><tr><td>&#x02003;&#x02003;Pollakiuria<sup>f</sup>
</td><td>1 (0.5)</td><td>2 (0.5)</td><td>21 (5.7)</td><td>11 (3.0)</td></tr><tr><td>&#x02003;&#x02003;Polyuria<sup>g</sup>
</td><td>0</td><td>0</td><td>2 (0.5)</td><td>2 (0.5)</td></tr><tr><td colspan="5">&#x02003;Volume-related AEs</td></tr><tr><td>&#x02003;&#x02003;Postural dizziness</td><td>1 (0.5)</td><td>1 (0.3)</td><td>2 (0.5)</td><td>2 (0.5)</td></tr><tr><td>&#x02003;&#x02003;Orthostatic hypotension</td><td>0</td><td>0</td><td>0</td><td>1 (0.3)</td></tr></tbody></table><table-wrap-foot><p>All AEs are reported, regardless of rescue medication</p><p>
<sup>a</sup>Possibly, probably or very likely related to study drug, as assessed by investigators</p><p>
<sup>b</sup>PBO/SITA, <italic>n</italic>&#x02009;=&#x02009;94; SITA 100 mg, <italic>n</italic>&#x02009;=&#x02009;172; CANA 100 mg, <italic>n</italic>&#x02009;=&#x02009;174; CANA 300 mg, <italic>n</italic>&#x02009;=&#x02009;165</p><p>
<sup>c</sup>Including balanitis, balanoposthitis and fungal genital infection</p><p>
<sup>d</sup>PBO/SITA, <italic>n</italic>&#x02009;=&#x02009;89; SITA 100 mg, <italic>n</italic>&#x02009;=&#x02009;194; CANA 100 mg, <italic>n</italic>&#x02009;=&#x02009;194; CANA 300 mg, <italic>n</italic>&#x02009;=&#x02009;202</p><p>
<sup>e</sup>Including vaginal infection, vaginal inflammation, vulvitis, vulvovaginal candidiasis, vulvovaginal mycotic infection and vulvovaginitis</p><p>
<sup>f</sup>Increased urine frequency</p><p>
<sup>g</sup>Increased urine volume</p><p>CANA, canagliflozin; PBO, placebo; SITA, sitagliptin</p></table-wrap-foot></table-wrap></p><p>Over 52&#x000a0;weeks, canagliflozin was associated with a higher incidence of genital mycotic infections in men and women. These were generally mild or moderate in intensity and led to few discontinuations; most (&#x0223c;80%) were reported during the first 26&#x000a0;weeks. The incidence of UTIs was similar across groups over 52&#x000a0;weeks. A higher incidence of AEs related to osmotic diuresis (i.e. pollakiuria [increased urine frequency], polyuria [increased urine volume]) was seen with canagliflozin vs sitagliptin and placebo/sitagliptin; most were mild in severity and infrequently led to discontinuation. The incidence of AEs related to reduced intravascular volume (i.e. postural dizziness, orthostatic hypotension) was low across groups; events with canagliflozin were mild to moderate in severity and none led to discontinuation.</p><p>The proportion of participants with documented episodes of hypoglycaemia over 52&#x000a0;weeks was 6.8% with both canagliflozin doses, 4.1% with sitagliptin and 2.7% with placebo/sitagliptin. One participant each receiving canagliflozin 100&#x000a0;mg and sitagliptin experienced a severe hypoglycaemic event. During weeks&#x000a0;26&#x02013;52 (period II), the incidence of documented hypoglycaemia was similar with canagliflozin 100&#x000a0;mg and 300&#x000a0;mg and sitagliptin (4.2%, 5.0% and 4.7%, respectively) and was higher than with placebo/sitagliptin (1.6%).</p><p>Over 52&#x000a0;weeks, decreases in alanine aminotransferase were observed with canagliflozin, whereas increases were seen with sitagliptin and placebo/sitagliptin (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Canagliflozin was associated with increased bilirubin, whereas decreases were seen with sitagliptin and placebo/sitagliptin. Increases in serum creatinine were observed across groups, being of a lower magnitude with canagliflozin than with sitagliptin or placebo/sitagliptin. All groups showed a reduction in eGFR. This reduction was observed by week&#x000a0;6 with canagliflozin and trended back toward baseline over time; eGFR progressively decreased with sitagliptin through week&#x000a0;18, followed by a small improvement. An increase in blood urea nitrogen was seen with canagliflozin vs sitagliptin and placebo/sitagliptin. Canagliflozin was associated with a decrease in serum urate, whereas an increase was seen with sitagliptin and placebo/sitagliptin. An increase in haemoglobin was seen with canagliflozin, whereas sitagliptin and placebo/sitagliptin were associated with decreased haemoglobin.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Summary of clinical laboratory variables at baseline and week&#x000a0;52</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>PBO/SITA</th><th>SITA 100&#x000a0;mg</th><th>CANA 100&#x000a0;mg</th><th>CANA 300&#x000a0;mg</th></tr></thead><tbody><tr><td>ALT, <italic>n</italic>
</td><td>137</td><td>282</td><td>294</td><td>293</td></tr><tr><td>&#x02003;Mean baseline, &#x003bc;kat/l</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td></tr><tr><td>&#x02003;Mean &#x000b1; SD per cent change</td><td>7.1&#x02009;&#x000b1;&#x02009;40.7</td><td>5.1&#x02009;&#x000b1;&#x02009;41.6</td><td>&#x02212;2.2&#x02009;&#x000b1;&#x02009;39.9</td><td>&#x02212;10.2&#x02009;&#x000b1;&#x02009;39.6</td></tr><tr><td>AST, <italic>n</italic>
</td><td>137</td><td>281</td><td>292</td><td>293</td></tr><tr><td>&#x02003;Mean baseline, &#x003bc;kat/l</td><td>0.4</td><td>0.4</td><td>0.4</td><td>0.4</td></tr><tr><td>&#x02003;Mean &#x000b1; SD per cent change</td><td>9.8&#x02009;&#x000b1;&#x02009;31.8</td><td>7.1&#x02009;&#x000b1;&#x02009;36.8</td><td>2.6&#x02009;&#x000b1;&#x02009;32.6</td><td>&#x02212;2.4&#x02009;&#x000b1;&#x02009;28.9</td></tr><tr><td>Bilirubin, <italic>n</italic>
</td><td>138</td><td>282</td><td>296</td><td>293</td></tr><tr><td>&#x02003;Mean baseline, &#x003bc;mol/l</td><td>9.1</td><td>8.7</td><td>9.0</td><td>8.5</td></tr><tr><td>&#x02003;Mean &#x000b1; SD per cent change</td><td>&#x02212;3.9&#x02009;&#x000b1;&#x02009;31.4</td><td>&#x02212;1.3&#x02009;&#x000b1;&#x02009;33.4</td><td>11.6&#x02009;&#x000b1;&#x02009;45.6</td><td>14.3&#x02009;&#x000b1;&#x02009;41.1</td></tr><tr><td>BUN, <italic>n</italic>
</td><td>139</td><td>282</td><td>296</td><td>295</td></tr><tr><td>&#x02003;Mean baseline, mmol/l</td><td>5.4</td><td>5.5</td><td>5.1</td><td>5.2</td></tr><tr><td>&#x02003;Mean &#x000b1; SD per cent change</td><td>5.9&#x02009;&#x000b1;&#x02009;33.8</td><td>3.5&#x02009;&#x000b1;&#x02009;26.6</td><td>14.8&#x02009;&#x000b1;&#x02009;26.7</td><td>16.1&#x02009;&#x000b1;&#x02009;33.4</td></tr><tr><td>Creatinine, <italic>n</italic>
</td><td>139</td><td>282</td><td>296</td><td>295</td></tr><tr><td>&#x02003;Mean baseline, &#x003bc;mol/l</td><td>73.9</td><td>72.0</td><td>71.4</td><td>70.2</td></tr><tr><td>&#x02003;Mean &#x000b1; SD per cent change</td><td>3.3&#x02009;&#x000b1;&#x02009;18.0</td><td>3.4&#x02009;&#x000b1;&#x02009;13.6</td><td>2.3&#x02009;&#x000b1;&#x02009;11.4</td><td>2.5&#x02009;&#x000b1;&#x02009;12.4</td></tr><tr><td>eGFR, <italic>n</italic>
</td><td>139</td><td>282</td><td>296</td><td>295</td></tr><tr><td>&#x02003;Mean baseline, ml min<sup>&#x02212;1</sup> (1.73&#x000a0;m<sup>2</sup>)<sup>&#x02212;1</sup>
</td><td>87.7</td><td>89.1</td><td>89.7</td><td>90.2</td></tr><tr><td>&#x02003;Mean &#x000b1; SD per cent change</td><td>&#x02212;1.4&#x02009;&#x000b1;&#x02009;18.2</td><td>&#x02212;2.4&#x02009;&#x000b1;&#x02009;12.8</td><td>&#x02212;1.4&#x02009;&#x000b1;&#x02009;12.8</td><td>&#x02212;1.5&#x02009;&#x000b1;&#x02009;12.9</td></tr><tr><td>Urate, <italic>n</italic>
</td><td>139</td><td>282</td><td>296</td><td>295</td></tr><tr><td>&#x02003;Mean baseline, &#x003bc;mol/l</td><td>333.4</td><td>328.8</td><td>316.6</td><td>311.2</td></tr><tr><td>&#x02003;Mean &#x000b1; SD per cent change</td><td>5.0&#x02009;&#x000b1;&#x02009;17.4</td><td>3.9&#x02009;&#x000b1;&#x02009;18.4</td><td>&#x02212;10.5&#x02009;&#x000b1;&#x02009;18.3</td><td>&#x02212;11.0&#x02009;&#x000b1;&#x02009;18.8</td></tr><tr><td>Haemoglobin, <italic>n</italic>
</td><td>134</td><td>277</td><td>292</td><td>285</td></tr><tr><td>&#x02003;Mean baseline, g/l</td><td>141.3</td><td>141.0</td><td>140.5</td><td>140.0</td></tr><tr><td>&#x02003;Mean &#x000b1; SD per cent change</td><td>&#x02212;1.6&#x02009;&#x000b1;&#x02009;6.0</td><td>&#x02212;1.6&#x02009;&#x000b1;&#x02009;6.2</td><td>4.0&#x02009;&#x000b1;&#x02009;7.2</td><td>3.7&#x02009;&#x000b1;&#x02009;7.1</td></tr></tbody></table><table-wrap-foot><p>ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CANA, canagliflozin; PBO, placebo; SITA, sitagliptin</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p>Patients with type 2 diabetes often require combination therapies to achieve and/or maintain effective glycaemic control [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In this study of patients with type 2 diabetes on background metformin, canagliflozin 100&#x000a0;mg and 300&#x000a0;mg significantly reduced HbA<sub>1c</sub> from baseline compared with placebo at week&#x000a0;26 and demonstrated non-inferiority to sitagliptin 100&#x000a0;mg in HbA<sub>1c</sub>-lowering effect at week&#x000a0;52; canagliflozin 300&#x000a0;mg also showed statistical superiority to sitagliptin in HbA<sub>1c</sub>-lowering effect. Significant decreases in FPG, body weight and systolic BP were seen with canagliflozin 100&#x000a0;mg and 300&#x000a0;mg vs placebo at week&#x000a0;26 and sitagliptin at week&#x000a0;52, with a sustained effect over 52&#x000a0;weeks. The 100&#x000a0;mg and 300&#x000a0;mg dosages of canagliflozin were associated with significant increases in HDL-cholesterol vs placebo at week&#x000a0;26, with increases from baseline also observed at week&#x000a0;52.</p><p>Increases from baseline in LDL-cholesterol were observed with canagliflozin and sitagliptin, with similar per cent changes at weeks&#x000a0;26 and 52. The mechanism of LDL-cholesterol increase with canagliflozin is unknown, but may reflect downstream metabolic effects of UGE and modest haemoconcentration resulting from an osmotic diuretic effect [<xref ref-type="bibr" rid="CR17">17</xref>]. Increases from baseline in non-HDL-cholesterol, which were smaller than those in LDL-cholesterol, were seen with canagliflozin and sitagliptin at weeks&#x000a0;26 and 52.</p><p>The safety and tolerability profile of canagliflozin was consistent with findings from previous Phase 3 studies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Canagliflozin was generally well tolerated, with a pattern of specific AEs (e.g. genital mycotic infections, osmotic diuresis-related AEs) that were generally mild or moderate in severity, occurred at a low incidence and infrequently led to discontinuation. The incidence of documented hypoglycaemia was low but was slightly higher with canagliflozin than with sitagliptin or placebo/sitagliptin. While the incidence of UTIs was similar with canagliflozin 100&#x000a0;mg and 300&#x000a0;mg and the control groups (i.e. sitagliptin and placebo/sitagliptin) in the current study, a small increase in the incidence of UTIs was observed with canagliflozin 100&#x000a0;mg (5.9%) compared with canagliflozin 300&#x000a0;mg and placebo (4.3% and 4.0%, respectively) in a pooled analysis across four placebo-controlled Phase 3 studies [<xref ref-type="bibr" rid="CR18">18</xref>]. The slight imbalance in overall AE incidence with canagliflozin 100 mg vs 300&#x000a0;mg was primarily driven by early events during period I; AE rates were more balanced during period II. In all groups except canagliflozin 300&#x000a0;mg, the incidence of AEs leading to discontinuation increased from week&#x000a0;26 to week&#x000a0;52; incidences were generally lower during period II relative to the entire 52&#x000a0;week period.</p><p>The results of the current study complement and support findings from a similar 52&#x000a0;week, Phase 3 study comparing canagliflozin 300&#x000a0;mg with sitagliptin 100&#x000a0;mg in patients with type 2 diabetes inadequately controlled with metformin plus sulfonylurea [<xref ref-type="bibr" rid="CR8">8</xref>]. In that study, canagliflozin 300&#x000a0;mg demonstrated non-inferiority and statistical superiority to sitagliptin in HbA<sub>1c</sub>-lowering effect at 52&#x000a0;weeks (difference in LS mean changes of &#x02212;0.37% [&#x02212;4.0&#x000a0;mmol/mol]). Greater reduction in body weight was observed with canagliflozin relative to sitagliptin (difference of &#x02212;2.8% [&#x02212;2.4&#x000a0;kg]); reductions in FPG and systolic BP were also seen with canagliflozin vs sitagliptin. Overall AE incidence was similar with canagliflozin and sitagliptin but the incidence of genital mycotic infection and osmotic diuresis-related AEs was higher with canagliflozin. The incidence of hypoglycaemia was similar with canagliflozin and sitagliptin but was higher than that observed in the current study, which is likely related to the additional sulfonylurea treatment in the previous study. Together with these previous results, the current findings provide additional evidence supporting the non-inferiority of canagliflozin 100&#x000a0;mg and 300&#x000a0;mg, and statistical superiority of canagliflozin 300&#x000a0;mg, to sitagliptin in HbA<sub>1c</sub>-lowering effect in patients with inadequate glycaemic control with their ongoing AHA therapy. Improvements in glycaemic control have also been observed with other SGLT2 inhibitors, and safety findings with canagliflozin in the current study were generally consistent with those seen with other SGLT2 inhibitors [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>The current study is strengthened by its placebo- and active-controlled design, allowing for comparison of canagliflozin with placebo (week&#x000a0;26) and sitagliptin (week&#x000a0;52). The study population reflects a typical profile of patients with type 2 diabetes (e.g. broad age range, mostly overweight/obese, wide range of racial/ethnic groups); thus, study results should be generalisable to a broad type 2 diabetes population. This study has several potential limitations. It was designed with pre-specified comparisons between canagliflozin and sitagliptin only at week&#x000a0;52, consistent with the assessment time point commonly used in other active-controlled studies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]; therefore, statistical comparisons of canagliflozin with sitagliptin at week&#x000a0;26 are not reported. Because type 2 diabetes is a chronic disorder, study durations beyond 52&#x000a0;weeks may better define the long-term efficacy and safety of canagliflozin. Studies comparing canagliflozin with other AHAs would also be useful for determining the relative efficacy/safety of canagliflozin as add-on therapy.</p><p>In summary, treatment with canagliflozin improved glycaemic control and reduced body weight compared with placebo over 26&#x000a0;weeks and with sitagliptin over 52&#x000a0;weeks and was generally well tolerated in patients whose type 2 diabetes was inadequately controlled with metformin monotherapy. These findings support the clinical usefulness of canagliflozin as add-on therapy in patients with type 2 diabetes.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec13"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="125_2013_3039_MOESM1_ESM.pdf"><label>ESM Table 1</label><caption><p>(PDF 17 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="125_2013_3039_MOESM2_ESM.pdf"><label>ESM Table 2</label><caption><p>(PDF 12 kb)</p></caption></media></supplementary-material></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>AE</term><def><p>Adverse event</p></def></def-item><def-item><term>AHA</term><def><p>Antihyperglycaemic agent</p></def></def-item><def-item><term>ANCOVA</term><def><p>Analysis of covariance</p></def></def-item><def-item><term>DPP-4</term><def><p>Dipeptidyl peptidase-4</p></def></def-item><def-item><term>eGFR</term><def><p>Estimated GFR</p></def></def-item><def-item><term>FPG</term><def><p>Fasting plasma glucose</p></def></def-item><def-item><term>IR</term><def><p>Immediate release</p></def></def-item><def-item><term>LOCF</term><def><p>Last observation carried forward</p></def></def-item><def-item><term>LS</term><def><p>Least squares</p></def></def-item><def-item><term>mITT</term><def><p>Modified intent-to-treat</p></def></def-item><def-item><term>MMTT</term><def><p>Mixed-meal tolerance test</p></def></def-item><def-item><term>PPG</term><def><p>Postprandial glucose</p></def></def-item><def-item><term>SGLT2</term><def><p>Sodium glucose co-transporter 2</p></def></def-item><def-item><term>SMBG</term><def><p>Self-monitored blood glucose</p></def></def-item><def-item><term>UGE</term><def><p>Urinary glucose excretion</p></def></def-item><def-item><term>UTI</term><def><p>Urinary tract infection</p></def></def-item><def-item><term>XR</term><def><p>Extended release</p></def></def-item></def-list></def-list></glossary><ack><title>Acknowledgements</title><p>The authors thank all investigators, study teams and patients for participating in this study. The authors acknowledge Felicity Schaeffer of Janssen Research &#x00026; Development, LLC, for her assistance and contribution to the clinical management, data review and preparation of the study report. Editorial support was provided by Lisa Shannon of MedErgy, and was funded by Janssen Global Services, LLC. Canagliflozin has been developed by Janssen Research &#x00026; Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation.</p><p>This study was previously presented, in part, in abstract form at the 48th Annual Meeting of the German Diabetes Association, Leipzig, Germany, 8&#x02013;11 May, 2013 and at the 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL, USA, 21&#x02013;25 June 2013.</p><sec id="d30e2829"><title>Funding</title><p>This study was supported by Janssen Research &#x00026; Development, LLC.</p></sec><sec id="d30e2834"><title>Duality of interest</title><p>FJL-G has served on advisory boards for Merck Sharpe and Dohme, Sanofi, Novo Nordisk, Janssen-Cilag, Lilly, Bristol-Myers Squibb/AstraZeneca and Takeda, has participated in speaker bureaus for Merck Sharpe and Dohme, Sanofi, Novo Nordisk, Janssen-Cilag, Lilly, Bristol-Myers Squibb/AstraZeneca, GlaxoSmithKline, Pfizer, Merck Serono, Silanes and Novartis, and has received research support from Merck Sharpe and Dohme, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Pfizer, Janssen-Cilag, Novartis and Novo Nordisk. AJ has received research support from Janssen. JD has served on advisory boards for Johnson and Johnson and Janssen. CT, RQ, WC and GM are full-time employees of Janssen Research &#x00026; Development, LLC.</p></sec><sec id="d30e2839"><title>Contribution statement</title><p>FJL-G, AJ, JD, RQ, WC and GM contributed to the design and conduct of the study and the acquisition, analysis and interpretation of data and also drafted, reviewed and approved the manuscript. CT contributed to the study design and the analysis and interpretation of data and drafted, reviewed and approved the manuscript. All authors approved the final version of the manuscript.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group><article-title>Standards of medical care in diabetes&#x02014;2012</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><fpage>S11</fpage><lpage>S63</lpage><pub-id pub-id-type="doi">10.2337/dc12-s011</pub-id><pub-id pub-id-type="pmid">22187469</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title><source>Diabetologia</source><year>2012</year><volume>55</volume><fpage>1577</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1007/s00125-012-2534-0</pub-id><pub-id pub-id-type="pmid">22526604</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">National Institute for Health and Clinical Excellence (2009) Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87. NICE, London</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagiannis</surname><given-names>T</given-names></name><name><surname>Paschos</surname><given-names>P</given-names></name><name><surname>Paletas</surname><given-names>K</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Tsapas</surname><given-names>A</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis</article-title><source>BMJ</source><year>2012</year><volume>344</volume><fpage>e1369</fpage><pub-id pub-id-type="doi">10.1136/bmj.e1369</pub-id><pub-id pub-id-type="pmid">22411919</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Aggarwal</surname><given-names>N</given-names></name><name><surname>Polidori</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><fpage>1232</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.2337/dc11-1926</pub-id><pub-id pub-id-type="pmid">22492586</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenlof</surname><given-names>K</given-names></name><name><surname>Cefalu</surname><given-names>WT</given-names></name><name><surname>Kim</surname><given-names>K-A</given-names></name><etal/></person-group><article-title>Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise</article-title><source>Diabetes Obes Metab</source><year>2013</year><volume>15</volume><fpage>372</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1111/dom.12054</pub-id><pub-id pub-id-type="pmid">23279307</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yale</surname><given-names>JF</given-names></name><name><surname>Bakris</surname><given-names>G</given-names></name><name><surname>Cariou</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</article-title><source>Diabetes Obes Metab</source><year>2013</year><volume>15</volume><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1111/dom.12090</pub-id><pub-id pub-id-type="pmid">23464594</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 36:2508&#x02013;2515</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Cefalu WT, Leiter LA, Yoon K-H et al (2013) Canagliflozin promotes body weight loss compared with glimepiride while providing glycaemic efficacy in subjects with type 2 diabetes on background metformin: 52-week findings from a randomised, double-blind trial. Lancet. doi:10.1016/S0140-6736(13)60683-2</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bode</surname><given-names>B</given-names></name><name><surname>Stenlof</surname><given-names>K</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Fung</surname><given-names>A</given-names></name><name><surname>Usiskin</surname><given-names>K</given-names></name></person-group><article-title>Efficacy and safety of canagliflozin in older subjects with type 2 diabetes: a randomized trial</article-title><source>Hosp Pract</source><year>2013</year><volume>41</volume><fpage>72</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.3810/hp.2013.04.1020</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>CJ</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Pieters</surname><given-names>A</given-names></name><name><surname>Bastien</surname><given-names>A</given-names></name><name><surname>List</surname><given-names>JF</given-names></name></person-group><article-title>Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>2223</fpage><lpage>2233</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60407-2</pub-id><pub-id pub-id-type="pmid">20609968</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>CJ</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Hennicken</surname><given-names>D</given-names></name><name><surname>Iqbal</surname><given-names>N</given-names></name><name><surname>Mansfield</surname><given-names>TA</given-names></name><name><surname>List</surname><given-names>JF</given-names></name></person-group><article-title>Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial</article-title><source>BMC Med</source><year>2013</year><volume>11</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/1741-7015-11-43</pub-id><pub-id pub-id-type="pmid">23425012</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Ramos</surname><given-names>SJ</given-names></name><name><surname>Salsali</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>List</surname><given-names>JF</given-names></name></person-group><article-title>Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>2217</fpage><lpage>2224</lpage><pub-id pub-id-type="doi">10.2337/dc10-0612</pub-id><pub-id pub-id-type="pmid">20566676</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ (2013) A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15:721&#x02013;728</mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Food and Drug Administration (2008) Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. FDA, Rockville, MD</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) (2012) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. CPMP/EWP/1080/00 Rev. 1. EMA, London</mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Weidmann P, de Courten M, Ferrari P (1992) Effect of diuretics on the plasma lipid profile. Eur Heart J 13(Suppl G):61&#x02013;67</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolle</surname><given-names>LE</given-names></name><name><surname>Capuano</surname><given-names>G</given-names></name><name><surname>Fung</surname><given-names>A</given-names></name><name><surname>Usiskin</surname><given-names>K</given-names></name></person-group><article-title>Urinary tract infection (UTI) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM)</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><fpage>A296</fpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Meininger</surname><given-names>G</given-names></name><name><surname>Sheng</surname><given-names>D</given-names></name><name><surname>Terranella</surname><given-names>L</given-names></name><name><surname>Stein</surname><given-names>PP</given-names></name></person-group><article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial</article-title><source>Diabetes Obes Metab</source><year>2007</year><volume>9</volume><fpage>194</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2006.00704.x</pub-id><pub-id pub-id-type="pmid">17300595</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>del Prato</surname><given-names>S</given-names></name><name><surname>Meier</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><fpage>2015</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.2337/dc11-0606</pub-id><pub-id pub-id-type="pmid">21816980</pub-id></element-citation></ref></ref-list></back></article>